Search results
FDA Approval of Alvotech/Teva Ustekinumab Biosimilar | JD Supra
JD Supra· 2 days agoOn April 16, Alvotech and Teva announced the FDA approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Johnson and Johnson’s STELERA® (ustekinumab). The product was approved as a subcutaneous ...
Reviva Pharmaceuticals (NASDAQ:RVPH) vs. Bristol-Myers Squibb (NYSE:BMY) Head to Head Survey
ETF DAILY NEWS· 12 hours agoBristol-Myers Squibb (NYSE:BMY – Get Free Report) and Reviva Pharmaceuticals (NASDAQ:RVPH – Get Free Report) are both medical companies, but which is the better investment? We will compare the ...
Does the Anti-Inflammatory Diet for Psoriasis Help Manage Symptoms?
Verywell Health via Yahoo News· 3 days agoInflammation is one of the underlying causes of psoriasis, and research shows that an...
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Ventyx...
FOX21 Colorado Springs· 5 days agoPomerantz LLP announces that a class action lawsuit has been filed against Ventyx Biosciences, Inc. ("Ventyx" or the "Company") (NASDAQ: VTYX) and certain officers. The class action, filed in ...
Western Wealth Management LLC Sells 3,258 Shares of Bristol-Myers Squibb (NYSE:BMY)
ETF DAILY NEWS· 4 days agoWestern Wealth Management LLC decreased its stake in Bristol-Myers Squibb (NYSE:BMY – Free Report) by 18.2% during the fourth quarter, Holdings Channel.com reports. The institutional investor ...
What Are the Most Effective Psoriasis Therapy Options?
Verywell Health via Yahoo News· 2 days agoWith many treatment options for psoriasis, how do you know which ones are right for you? Here are...
Novartis (NVS) Q1 Earnings, Sales Beat, Guidance Raised
Zacks via Yahoo Finance· 2 days agoIn October 2023, the FDA approved Cosentyx for treating moderate-to-severe hidradenitis suppurativa...
More people exposed to Manhattan Project chemicals deserve compensation, advocates say
Fox News via Yahoo News· 14 hours agoMissouri Sen. Josh Hawley is pushing to expand payments to those exposed to Manhattan Project...
Pharma Stock Roundup: JNJ's Q1 Results, LLY, ABBV, RHHBY's Successful Study Data
Zacks via Yahoo Finance· 6 days agoData from the SURMOUNT-OSA studies showed that treatment with tirzepatide resulted in a mean AHI...
TD Cowen Lowers Amgen (NASDAQ:AMGN) Price Target to $360.00
ETF DAILY NEWS· 6 days agoAmgen (NASDAQ:AMGN – Get Free Report) had its price target dropped by TD Cowen from $370.00 to $360.00 in a research note issued on Wednesday, Benzinga reports. The brokerage currently has a ...